NASDAQ$ERAS
Erasca Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Erasca reported Q3 2021 financial results and business updates, highlighting strong execution with four ongoing clinical trials and recognition as a Fierce Biotech 'Fierce 15' company.
Erasca reported a net loss of $46.1 million for the quarter ended September 30, 2021, inclusive of a $17.5 million expense for common shares issued to the Erasca Foundation. The company's cash position remains strong at $486.6 million, which is expected to fund operations for at least the next 24 months. Erasca has four ongoing clinical trials.
- Dosed first patient in HERKULES-2 and HERKULES-3 trials evaluating ERAS-007 in non-small cell lung cancer and gastrointestinal malignancies, respectively.
- Presented preclinical data for ERAS-801, a CNS-penetrant EGFR inhibitor, at AACR Special Virtual Conference on Brain Cancer.
- Completed a $345 million initial public offering in July 2021.
- Cash, cash equivalents, and investments were $486.6 million as of September 30, 2021.
Headline financials
Revenue & EPS history
Erasca · Revenue · Quarterly
$0
Forward guidance
Erasca anticipates filing an IND for ERAS-801 in the first quarter of 2022 and expects to dose the first patient in the HERKULES-4 trial in the first quarter of 2022.
Tailwinds
- IND filing expected in first quarter of 2022 for ERAS-801 (CNS-penetrant EGFR inhibitor)
- Dosing of the first patient expected in first quarter of 2022 for HERKULES-4 (Phase 1b/2 clinical trial for ERAS-007/MAPKlamp)
- Multiple clinical data readouts anticipated in 2022.
- Planned IND filings for ERAS-801 in Q1 2022.
- Planned IND filings for ERAS-3490 in second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2021
+1.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+11.0%
Q3 2022
Best reaction
-10.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | +1.0% | +32.1% | |
| Q4 2025 | -4.3% | -7.8% | +16.1% | |
| Q3 2025 | -4.2% | +7.9% | +35.8% | |
| Q1 2025 | -4.0% | -5.8% | +9.3% | |
| Q4 2024 | +6.0% | -8.2% | +25.0% | |
| Q3 2024 | -8.4% | -14.1% | -15.4% | |
| Q2 2024 | +8.3% | +16.7% | +27.9% | |
| Q1 2024 | -10.1% | -12.8% | +8.9% | |
| Q4 2023 | +4.0% | +9.1% | -4.5% | |
| Q3 2023 | -8.6% | -1.8% | -15.0% | |
| Q2 2023 | +10.6% | -3.2% | -0.8% | |
| Q1 2023 | -1.0% | -3.8% | -5.6% | |
| Q4 2022 | -2.7% | -5.8% | -3.8% | |
| Q3 2022 | +11.0% | +20.7% | -19.1% | |
| Q2 2022 | +2.5% | +4.4% | -10.8% | |
| Q1 2022 | +2.8% | +9.4% | -4.6% | |
| Q4 2021 | +9.1% | +8.1% | -9.7% | |
| Q3 2021 | +2.2% | -3.1% | -28.9% | |
| Q2 2021 | +4.8% | +8.9% | -12.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro